Why Canopy Growth (TSX:WEED) Is a Good Buy Right Now

If you’re waiting for Canopy Growth Corp (TSX:WEED)(NYSE:CGC) to sink back to $36 per share, you’re dreaming.

| More on:
Hand writing Time for Action concept with red marker on transparent wipe board.

Image source: Getty Images

If you’re waiting around for Canopy Growth (TSX:WEED)(NYSE:CGC) to sink back to the $35 level it hit last November, you’re dreaming.

While this stock may not hit that $100 mark until it makes a serious profit, I’m a believer that this stock is making the right moves to keep itself on top.

Canopy Growth is now in a set-up period, pushing forward with acquisitions, partnerships, research, and development to come out as the main source of production for not just Canada, but throughout North America.

And right now, this stock is on a dip. The company almost hit its all-time high of $74 per share back in late April, but since then the stock has gone back down to around the $60 mark at the time of writing. While it might go a bit up or a bit down from there in the short term, I believe over the long term this stock will continue to trend upwards. Let’s look at why.

Partnerships

It’s no secret that Canopy Growth has been making some strong partnerships over the last year. It all started with Constellation Brands, with the beverage company putting billions into Canopy’s pocket. The partnership gave it access to the United States; almost immediately, Canopy announced it had been approved to start hemp production in New York State.

After that came the acquisition of Acreage Holdings, with the company requiring to pay about $400 million now and $4.57 billion once legalization comes through in the United States. That’s a lot of cash for Canopy to hand out, so it must be super confident that it can dish it out when — and if — the time comes.

Most recently, Canopy has taken an entirely new approach and partnered with This Works, a cosmetics company that plans to introduce “cannabis-infused products to the global beauty, wellness, and sleep solution space.” There just aren’t any other big names pushing into this area, and while it may not be as large as cannabis-infused beverages, the company is already there, so why not expand further?

Production

This all means Canopy needs to produce like crazy, and soon. Canopy now has 4.3 million square feet of licensed growing space ready to go and expansion plans in place for even more. How much it’ll be able to produce remains a bit of a mystery, but the number is at least in the hundreds of thousands of kilograms per year.

This is a start and definitely puts it at the head of the pack in terms of production, but it’s the techniques that also have analysts happy about the business’s performance. The company consistently improves its production techniques, reducing the cost of production per gram by 18% quarter over quarter and 32% year over year. This is partially due to how much space the company has and due to the company’s constant research and development of its production.

Price

If you look at Canopy’s financials, it’s clear to see the company is moving closer and closer to announcing some major gains. This set-up process through partnerships and production means as soon as legalization hits in the United States, Canopy is going to go crazy. It could turn a corner where it suddenly becomes like Shopify and jumps through the roof.

Analysts believe the stock is slightly undervalued and could hit $100 in the next 12 months. A recession could push it down, but, as I’ve said, it’s likely to just jump back up again and then some.

That day could be closer than we think.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth. Tom Gardner owns shares of Shopify. The Motley Fool owns shares of Shopify and Shopify. Shopify is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »